HRP20110514T1 - Dimerni spojevi kao agonisti receptora fgf - Google Patents
Dimerni spojevi kao agonisti receptora fgf Download PDFInfo
- Publication number
- HRP20110514T1 HRP20110514T1 HR20110514T HRP20110514T HRP20110514T1 HR P20110514 T1 HRP20110514 T1 HR P20110514T1 HR 20110514 T HR20110514 T HR 20110514T HR P20110514 T HRP20110514 T HR P20110514T HR P20110514 T1 HRP20110514 T1 HR P20110514T1
- Authority
- HR
- Croatia
- Prior art keywords
- radical
- alk
- carbon atoms
- nr6r7
- unbranched
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 16
- 108091008794 FGF receptors Proteins 0.000 title claims abstract 5
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 title claims abstract 5
- 239000000018 receptor agonist Substances 0.000 title claims abstract 4
- 229940044601 receptor agonist Drugs 0.000 title claims abstract 4
- -1 alkyl radical Chemical class 0.000 claims abstract 104
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 71
- 150000003254 radicals Chemical class 0.000 claims abstract 50
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 33
- 125000005843 halogen group Chemical group 0.000 claims abstract 26
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims abstract 17
- 229910052799 carbon Inorganic materials 0.000 claims abstract 16
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims abstract 13
- 125000004429 atom Chemical group 0.000 claims abstract 13
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 10
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims abstract 9
- 239000000178 monomer Substances 0.000 claims abstract 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 7
- 125000003118 aryl group Chemical group 0.000 claims abstract 7
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 7
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- 125000005647 linker group Chemical group 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 claims 8
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- 230000004083 survival effect Effects 0.000 claims 6
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- JMANUKZDKDKBJP-UHFFFAOYSA-N imidazo[1,5-a]pyridine Chemical compound C1=CC=CC2=CN=CN21 JMANUKZDKDKBJP-UHFFFAOYSA-N 0.000 claims 3
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000033386 Buerger disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 206010003230 arteritis Diseases 0.000 claims 2
- 210000001367 artery Anatomy 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 210000003780 hair follicle Anatomy 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009756 muscle regeneration Effects 0.000 claims 2
- 210000003098 myoblast Anatomy 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- 230000020341 sensory perception of pain Effects 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- ITAHAJZOJDYBDM-UHFFFAOYSA-N 2-amino-5-[1-[[3-[2-[2-[2-[3-[[3-(4-amino-3-carboxybenzoyl)-2-methylindolizin-1-yl]carbamoyl]phenoxy]ethoxy]ethoxy]ethoxy]benzoyl]amino]-2-methylindolizine-3-carbonyl]benzoic acid Chemical compound C=12C=CC=CN2C(C(=O)C=2C=C(C(N)=CC=2)C(O)=O)=C(C)C=1NC(=O)C(C=1)=CC=CC=1OCCOCCOCCOC(C=1)=CC=CC=1C(=O)NC(=C1C=CC=CN11)C(C)=C1C(=O)C1=CC=C(N)C(C(O)=O)=C1 ITAHAJZOJDYBDM-UHFFFAOYSA-N 0.000 claims 1
- DIYIJXCRRNYRPM-UHFFFAOYSA-N 2-amino-5-[1-[[4-[2-[2-[2-[4-[[3-(4-amino-3-carboxybenzoyl)-2-methylindolizin-1-yl]carbamoyl]phenoxy]ethoxy]ethoxy]ethoxy]benzoyl]amino]-2-methylindolizine-3-carbonyl]benzoic acid Chemical compound C=12C=CC=CN2C(C(=O)C=2C=C(C(N)=CC=2)C(O)=O)=C(C)C=1NC(=O)C(C=C1)=CC=C1OCCOCCOCCOC(C=C1)=CC=C1C(=O)NC(=C1C=CC=CN11)C(C)=C1C(=O)C1=CC=C(N)C(C(O)=O)=C1 DIYIJXCRRNYRPM-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- RRBUUZXEFCEBKE-UHFFFAOYSA-L [Na+].[Na+].C(CCCCCNC(COC1=CC=C(C=C1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC1=CC=C(C=C1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O Chemical compound [Na+].[Na+].C(CCCCCNC(COC1=CC=C(C=C1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC1=CC=C(C=C1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O RRBUUZXEFCEBKE-UHFFFAOYSA-L 0.000 claims 1
- QEVDHOOUGNXMMV-UHFFFAOYSA-L [Na+].[Na+].C(CCCCCNC(COC=1C=C(C=CC=1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC=1C=C(C=CC=1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O Chemical compound [Na+].[Na+].C(CCCCCNC(COC=1C=C(C=CC=1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC=1C=C(C=CC=1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O QEVDHOOUGNXMMV-UHFFFAOYSA-L 0.000 claims 1
- GMDLMCKKBMPWNE-UHFFFAOYSA-L [Na+].[Na+].C(CCCNC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O Chemical compound [Na+].[Na+].C(CCCNC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O GMDLMCKKBMPWNE-UHFFFAOYSA-L 0.000 claims 1
- RXLUXAULKDQFQQ-UHFFFAOYSA-L [Na+].[Na+].C(CCNC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O Chemical compound [Na+].[Na+].C(CCNC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O RXLUXAULKDQFQQ-UHFFFAOYSA-L 0.000 claims 1
- PQLMFWOZNIJVLX-UHFFFAOYSA-L [Na+].[Na+].C(CNC(COC1=CC=C(C=C1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC1=CC=C(C=C1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O Chemical compound [Na+].[Na+].C(CNC(COC1=CC=C(C=C1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC1=CC=C(C=C1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O PQLMFWOZNIJVLX-UHFFFAOYSA-L 0.000 claims 1
- NUVJBHTZJGFJRP-UHFFFAOYSA-L [Na+].[Na+].C(CNC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O Chemical compound [Na+].[Na+].C(CNC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O)NC(COC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)=O NUVJBHTZJGFJRP-UHFFFAOYSA-L 0.000 claims 1
- POLBWBYXOKXZHA-UHFFFAOYSA-L [Na+].[Na+].O(CCOCCOC=1C=C(C=CC=1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)CCOCCOC=1C=C(C=CC=1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C Chemical compound [Na+].[Na+].O(CCOCCOC=1C=C(C=CC=1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)CCOCCOC=1C=C(C=CC=1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C POLBWBYXOKXZHA-UHFFFAOYSA-L 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- IYRWEQXVUNLMAY-UHFFFAOYSA-N carbonyl fluoride Chemical group FC(F)=O IYRWEQXVUNLMAY-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229920001577 copolymer Chemical class 0.000 claims 1
- UTSFJXRRBDGTKN-UHFFFAOYSA-L disodium 2-amino-5-[1-[4-[2-[2-[2-[2-[4-[3-(4-amino-3-carboxylatobenzoyl)-2-methylindolizin-1-yl]phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]phenyl]-2-methylindolizine-3-carbonyl]benzoate Chemical compound [Na+].[Na+].O(CCOCCOC1=CC=C(C=C1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)CCOCCOC1=CC=C(C=C1)C=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C UTSFJXRRBDGTKN-UHFFFAOYSA-L 0.000 claims 1
- LANDJJVXYPTXPJ-UHFFFAOYSA-L disodium 2-amino-5-[1-[[3-[2-[2-[3-[[3-(4-amino-3-carboxylatobenzoyl)-2-methylindolizin-1-yl]carbamoyl]phenoxy]ethylcarbamoylamino]ethoxy]benzoyl]amino]-2-methylindolizine-3-carbonyl]benzoate Chemical compound [Na+].[Na+].C(=O)(NCCOC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)NCCOC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C LANDJJVXYPTXPJ-UHFFFAOYSA-L 0.000 claims 1
- CENHTGZZVXBSNX-UHFFFAOYSA-L disodium 2-amino-5-[1-[[3-[2-[[4-[2-[3-[[3-(4-amino-3-carboxylatobenzoyl)-2-methylindolizin-1-yl]carbamoyl]phenoxy]ethylamino]-4-oxobutanoyl]amino]ethoxy]benzoyl]amino]-2-methylindolizine-3-carbonyl]benzoate Chemical compound [Na+].[Na+].O=C(CCC(=O)NCCOC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)NCCOC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C CENHTGZZVXBSNX-UHFFFAOYSA-L 0.000 claims 1
- OOWSCZLYEYZHKH-UHFFFAOYSA-L disodium 2-amino-5-[1-[[3-[8-[3-[[3-(4-amino-3-carboxylatobenzoyl)-2-methylindolizin-1-yl]carbamoyl]phenoxy]octoxy]benzoyl]amino]-2-methylindolizine-3-carbonyl]benzoate Chemical compound [Na+].[Na+].C(CCCCCCCOC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C)OC=1C=C(C=CC=1)C(=O)NC=1C(=C(N2C=CC=CC=12)C(=O)C=1C=C(C(=O)[O-])C(=CC=1)N)C OOWSCZLYEYZHKH-UHFFFAOYSA-L 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 238000006884 silylation reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0600317A FR2896247B1 (fr) | 2006-01-13 | 2006-01-13 | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| PCT/FR2007/000051 WO2007080325A1 (fr) | 2006-01-13 | 2007-01-12 | Composes dimeres agonistes des recepteurs des fgfs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110514T1 true HRP20110514T1 (hr) | 2011-08-31 |
Family
ID=36808846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110514T HRP20110514T1 (hr) | 2006-01-13 | 2011-07-11 | Dimerni spojevi kao agonisti receptora fgf |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9120819B2 (ko) |
| EP (1) | EP2018165B1 (ko) |
| JP (1) | JP5286088B2 (ko) |
| KR (1) | KR101378220B1 (ko) |
| CN (1) | CN101384258B (ko) |
| AR (1) | AR059001A1 (ko) |
| AT (1) | ATE505188T1 (ko) |
| AU (1) | AU2007204252B2 (ko) |
| BR (1) | BRPI0707132A2 (ko) |
| CA (1) | CA2633057C (ko) |
| CR (1) | CR10097A (ko) |
| CY (1) | CY1111688T1 (ko) |
| DE (1) | DE602007013889D1 (ko) |
| DK (1) | DK2018165T3 (ko) |
| EA (1) | EA015046B1 (ko) |
| EC (1) | ECSP088592A (ko) |
| ES (1) | ES2364857T3 (ko) |
| FR (1) | FR2896247B1 (ko) |
| HK (1) | HK1130009A1 (ko) |
| HN (1) | HN2008001067A (ko) |
| HR (1) | HRP20110514T1 (ko) |
| IL (1) | IL192403A (ko) |
| JO (1) | JO2659B1 (ko) |
| MA (1) | MA30214B1 (ko) |
| MX (1) | MX2008009010A (ko) |
| NO (1) | NO20083406L (ko) |
| NZ (1) | NZ569631A (ko) |
| PE (1) | PE20071115A1 (ko) |
| PL (1) | PL2018165T3 (ko) |
| PT (1) | PT2018165E (ko) |
| RS (1) | RS51872B (ko) |
| SI (1) | SI2018165T1 (ko) |
| TN (1) | TNSN08250A1 (ko) |
| TW (1) | TWI386408B (ko) |
| UA (1) | UA95469C2 (ko) |
| WO (1) | WO2007080325A1 (ko) |
| ZA (1) | ZA200806547B (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2883286B1 (fr) * | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
| EP2270043A1 (en) | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| US9226960B2 (en) | 2010-04-16 | 2016-01-05 | Andrew B. Bush | FGF modulation of in vivo antibody production and humoral immunity |
| FR2962437B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
| FR2962438B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'indolizines, procedes de preparation et application en therapeutique |
| US8901341B2 (en) | 2011-02-11 | 2014-12-02 | Bezwada Biomedical, Llc | Amino acid derivatives and absorbable polymers therefrom |
| WO2012167261A2 (en) | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
| FR2982261B1 (fr) * | 2011-11-04 | 2014-06-13 | Galderma Res & Dev | Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique |
| FR2985257B1 (fr) * | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| FR2985258A1 (fr) | 2011-12-28 | 2013-07-05 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| FR2985185B1 (fr) * | 2012-01-04 | 2013-12-27 | Sanofi Sa | Utilisation en therapeutique de derives d'imidazopyridine |
| AU2014233520B2 (en) | 2013-03-15 | 2019-02-21 | The Regents Of The University Of California | Modulators of the eIF2alpha pathway |
| EP2994130A4 (en) * | 2013-05-06 | 2017-02-22 | Bush, Andrew B. | Fgf modulation of in vivo antibody production and humoral immunity |
| CN108601863A (zh) | 2015-12-11 | 2018-09-28 | 国家儿童医院研究所 | 用于优化的患者特异性组织工程化血管移植物的系统和方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193926A (en) | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| ES2360182T3 (es) | 2002-05-07 | 2011-06-01 | Novo Nordisk A/S | Formulaciones solubles que comprenden insulina monomérica e insulina acilada. |
| FR2859997B1 (fr) * | 2003-09-18 | 2006-02-03 | Sanofi Synthelabo | Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant. |
-
2006
- 2006-01-13 FR FR0600317A patent/FR2896247B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-11 JO JO20078A patent/JO2659B1/en active
- 2007-01-12 JP JP2008549908A patent/JP5286088B2/ja not_active Expired - Fee Related
- 2007-01-12 BR BRPI0707132-9A patent/BRPI0707132A2/pt not_active IP Right Cessation
- 2007-01-12 ES ES07717861T patent/ES2364857T3/es active Active
- 2007-01-12 DE DE602007013889T patent/DE602007013889D1/de active Active
- 2007-01-12 EA EA200870167A patent/EA015046B1/ru not_active IP Right Cessation
- 2007-01-12 KR KR1020087019763A patent/KR101378220B1/ko not_active IP Right Cessation
- 2007-01-12 PL PL07717861T patent/PL2018165T3/pl unknown
- 2007-01-12 NZ NZ569631A patent/NZ569631A/en not_active IP Right Cessation
- 2007-01-12 MX MX2008009010A patent/MX2008009010A/es active IP Right Grant
- 2007-01-12 PT PT07717861T patent/PT2018165E/pt unknown
- 2007-01-12 CA CA2633057A patent/CA2633057C/fr not_active Expired - Fee Related
- 2007-01-12 DK DK07717861.4T patent/DK2018165T3/da active
- 2007-01-12 SI SI200730643T patent/SI2018165T1/sl unknown
- 2007-01-12 PE PE2007000034A patent/PE20071115A1/es not_active Application Discontinuation
- 2007-01-12 AU AU2007204252A patent/AU2007204252B2/en not_active Ceased
- 2007-01-12 AR ARP070100146A patent/AR059001A1/es not_active Application Discontinuation
- 2007-01-12 TW TW096101264A patent/TWI386408B/zh not_active IP Right Cessation
- 2007-01-12 ZA ZA200806547A patent/ZA200806547B/xx unknown
- 2007-01-12 WO PCT/FR2007/000051 patent/WO2007080325A1/fr active Application Filing
- 2007-01-12 RS RS20110305A patent/RS51872B/en unknown
- 2007-01-12 AT AT07717861T patent/ATE505188T1/de active
- 2007-01-12 CN CN2007800052555A patent/CN101384258B/zh not_active Expired - Fee Related
- 2007-01-12 EP EP07717861A patent/EP2018165B1/fr active Active
- 2007-12-01 UA UAA200810356A patent/UA95469C2/ru unknown
-
2008
- 2008-06-10 TN TNP2008000250A patent/TNSN08250A1/en unknown
- 2008-06-20 CR CR10097A patent/CR10097A/es not_active IP Right Cessation
- 2008-06-23 IL IL192403A patent/IL192403A/en not_active IP Right Cessation
- 2008-07-01 EC EC2008008592A patent/ECSP088592A/es unknown
- 2008-07-10 HN HN2008001067A patent/HN2008001067A/es unknown
- 2008-07-11 US US12/171,373 patent/US9120819B2/en not_active Expired - Fee Related
- 2008-08-04 NO NO20083406A patent/NO20083406L/no not_active Application Discontinuation
- 2008-08-08 MA MA31166A patent/MA30214B1/fr unknown
-
2009
- 2009-09-02 HK HK09108015.5A patent/HK1130009A1/xx not_active IP Right Cessation
-
2011
- 2011-07-11 HR HR20110514T patent/HRP20110514T1/hr unknown
- 2011-07-13 CY CY20111100683T patent/CY1111688T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110514T1 (hr) | Dimerni spojevi kao agonisti receptora fgf | |
| HRP20161306T1 (hr) | Dimerni spojevi kao agonisti receptora fgf (fgfr), postupak za njihovu pripravu i njihova terapijska uporaba | |
| RU2014131065A (ru) | Димерные соединения-агонисты рецептора fgf ( fgfr ), способ их получения и их терапевтическое применение | |
| RU2009106934A (ru) | Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента | |
| EP2266946A3 (en) | Compound For The Treatment Of Metabolic Disorders | |
| JP2008509166A5 (ko) | ||
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| JP2009504763A5 (ko) | ||
| HK1083462A1 (en) | Compounds for the treatment of metabolic disorders | |
| RU2008119842A (ru) | Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1 | |
| JP2013532652A5 (ko) | ||
| RU2013151174A (ru) | Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы | |
| JP2009530392A5 (ko) | ||
| EP2251327A3 (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
| UA102679C2 (ru) | Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии | |
| ATE311358T1 (de) | Immunoregulierende verbindungen, deren derivate und ihre verwendung | |
| PT1202957E (pt) | Aminobenzofenonas como inibidoras de il-1beta e tnf-alpha | |
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| JP2011506588A5 (ko) | ||
| JP2004517843A5 (ko) | ||
| RU2009125439A (ru) | Комбинация ингибитора гда и антиметаболита | |
| JP2006503805A5 (ko) | ||
| CA2502347A1 (en) | 9a-azalides with anti-inflammatory activity | |
| JP2018529648A5 (ko) | ||
| JP2005501870A5 (ko) |